Non-dilutive financing is redefining late-stage development economics. Teva’s $400 million Blackstone deal for duvakitug and Royalty Pharma’s APAC expansion signal that asset-specific capital—not balance-sheet debt—is the 2026 playbook for de-risking Phase 3 programs while preserving equity upside. Meanwhile, UCB secured worldwide rights to Antengene’s CD19 T-cell engager for over $1.1 billion, and Johnson & Johnson’s nipocalimab received its fifth FDA Fast Track designation, this time for systemic lupus erythematosus.

Top Story: Teva/Blackstone $400M Strategic Funding for Duvakitug

What Happened: Teva Pharmaceutical Industries and Blackstone Life Sciences announced a $400 million strategic funding agreement spread across four years to support continued clinical development of duvakitug, a human monoclonal antibody targeting TL1A.

Deal Structure:

• Total funding: $400 million over four years
• Blackstone compensation: Regulatory and commercial milestones plus low single-digit royalties on worldwide sales
• Development focus: Phase 3 studies in ulcerative colitis and Crohn’s disease
• Partnership: Co-developed with Sanofi

Duvakitug Profile:

Duvakitug is a monoclonal antibody targeting TL1A (TNF-like ligand 1A), a cytokine implicated in inflammatory bowel disease pathogenesis.

TL1A Mechanism:

TL1A (TNFSF15) is a member of the TNF superfamily that:

• Promotes inflammatory responses in gut tissue
• Activates T cells and drives chronic inflammation
• Is elevated in IBD patients
• Represents novel mechanism distinct from anti-TNF therapies

Why TL1A Matters:

The target is being called “the next TNF” in IBD because:

• Genetic studies link TL1A to IBD susceptibility
• Expression is elevated specifically in inflamed intestinal tissue
• Blocking TL1A reduces inflammation in preclinical models
• Offers alternative mechanism for anti-TNF non-responders

Current Development Status:

Duvakitug is in Phase 3 trials for:

• Ulcerative colitis: Inflammatory condition affecting colon
• Crohn’s disease: Inflammatory condition affecting entire GI tract

Both indications represent large markets with ~1.6 million U.S. IBD patients seeking better treatment options.

Competitive Landscape:

Multiple companies developing TL1A inhibitors:

• Merck: MK-7240 in Phase 2
• Sanofi/Teva: Duvakitug (this program) in Phase 3
• Prometheus Biosciences (acquired by Merck): Additional TL1A assets

The $400 million Blackstone financing validates TL1A as high-conviction mechanism, creating competitive race for first approval.

Why Non-Dilutive Financing Matters:

Traditional Phase 3 funding options:

Equity financing:

• Dilutes existing shareholders
• Gives new investors ownership at potentially depressed valuations
• Reduces upside capture for current shareholders

Balance sheet debt:

• Interest payments burden cash flow
• Covenant restrictions limit operational flexibility
• Risk to entire company if program fails

Asset-specific financing (Blackstone model):

• No equity dilution
• Blackstone compensated through milestones and low single-digit royalties
• Risk limited to specific asset rather than company-wide debt
• Preserves shareholder upside if duvakitug succeeds

The 2026 Capital Playbook:

This deal exemplifies trend toward asset-specific capital for Phase 3-ready programs with:

• De-risked clinical profiles (positive Phase 2 data)
• Large market opportunities (IBD affects millions)
• Clear regulatory paths
• Institutional validation (Sanofi partnership)

Market Implications:

If approved (potential 2027-2028 timeline):

• IBD market exceeds $10 billion annually
• TL1A inhibitors could capture share from anti-TNF therapies and JAK inhibitors
• Sanofi/Teva partnership provides global commercialization infrastructure
• Blackstone’s low single-digit royalties suggest confidence in substantial sales

What to Watch: Phase 3 trial readouts (expected 2026-2027), competitive TL1A data from Merck, regulatory filing timelines, and commercial preparation.

UCB/Antengene: $1.1B CD19 T-Cell Engager Deal

What Happened: UCB secured worldwide exclusive rights to ATG-201, Antengene’s CD19/CD3 bispecific T-cell engager for autoimmune diseases.

Deal Terms:

• Upfront payment: $80 million
• Milestone potential: Over $1.1 billion in success-based milestones
• Royalties: Tiered royalties on future sales
• Rights: Worldwide exclusive license

ATG-201 Technology:

ATG-201 is a bispecific antibody that:

• Simultaneously binds CD19 (on B cells) and CD3 (on T cells)
• Brings T cells into proximity with B cells
• Activates T cells to kill B cells
• Depletes pathogenic B cells driving autoimmune disease

The Steric Hindrance Masking Innovation:

Antengene’s proprietary technology uses steric hindrance masking to:

• Shield T-cell engaging domain until reaching target tissue
• Reduce systemic T-cell activation
• Minimize cytokine release syndrome (CRS) risk
• Improve therapeutic index

Why CRS Reduction Matters:

T-cell engagers used in oncology cause significant CRS:

• Massive cytokine release (IL-6, TNF-alpha, others)
• Fever, hypotension, organ dysfunction
• Potentially life-threatening complications
• Requires intensive monitoring and management

Oncology vs. Autoimmune Setting:

In cancer, CRS risk is acceptable given disease severity. In autoimmune diseases:

• Patients are typically younger and otherwise healthy
• Chronic treatment may be required
• Safety bar is much higher
• CRS would severely limit adoption

Reducing CRS through masking technology is critical for autoimmune TCE success.

CD19 Target Rationale:

CD19 is expressed on:

• All B cells from early development through maturation
• B cells producing pathogenic autoantibodies
• Not on plasma cells or other immune cells

Depleting CD19+ B cells addresses multiple autoimmune diseases where B cells drive pathology:

• Systemic lupus erythematosus (SLE)
• Rheumatoid arthritis
• Myasthenia gravis
• Multiple sclerosis
• Others

Competitive Context:

Current B-cell depletion therapies:

• Rituximab (anti-CD20): Approved for some autoimmune indications
• Ocrelizumab (anti-CD20): Approved for MS
• Other anti-CD20s: Various development stages

T-cell engagers offer potential advantages:

• More potent B-cell depletion
• Different mechanism vs. antibody-dependent cell killing
• Possibility of deeper, more durable responses

Market Opportunity:

If successful across multiple autoimmune indications:

• SLE: ~300,000 U.S. patients
• Rheumatoid arthritis: ~1.3 million U.S. patients
• Myasthenia gravis: ~60,000 U.S. patients
• Multiple sclerosis: ~1 million U.S. patients

Combined addressable market exceeds $20 billion annually.

Development Timeline:

• First-in-human data: Expected 2027
• Phase 2: 2027-2028 if Phase 1 successful
• Potential approval: 2029-2030 earliest

The $1.1B Validation:

The massive milestone structure validates:

• Antengene’s masking technology as differentiated
• T-cell engagers as viable approach in autoimmune disease
• CD19 as compelling target
• UCB’s conviction in the asset

What to Watch: Phase 1 trial initiation, safety data particularly CRS incidence, efficacy signals in initial autoimmune indication, and competitive T-cell engager programs.

J&J Nipocalimab: Fifth FDA Fast Track Designation

What Happened: Johnson & Johnson’s nipocalimab received FDA Fast Track designation for systemic lupus erythematosus (SLE), marking the drug’s fifth Fast Track across autoantibody-driven indications.

Previous Fast Track Designations:

1. HDFN: Hemolytic disease of the fetus and newborn
2. wAIHA: Warm autoimmune hemolytic anemia
3. gMG: Generalized myasthenia gravis
4. Sjögren’s syndrome
5. SLE: Systemic lupus erythematosus (new)

Fast Track Benefits:

• More frequent FDA meetings and communications
• Eligibility for accelerated approval if criteria met
• Rolling review (submitting NDA sections as completed)
• Priority review eligibility

Nipocalimab Mechanism:

Nipocalimab is an FcRn (neonatal Fc receptor) blocker that:

• Binds FcRn preventing IgG recycling
• Accelerates pathogenic antibody clearance
• Reduces autoantibody levels
• Addresses root cause across multiple autoantibody diseases

The “Rolling Review” Strategy:

J&J’s fifth Fast Track suggests aggressive development approach:

• Simultaneous trials across multiple indications
• Sequential regulatory filings as data mature
• Building comprehensive safety database across populations
• Potential for multiple near-simultaneous approvals

SLE Indication:

Phase 2b JASMINE Results:

The trial showed:

• Reduction in lupus disease activity
• Steroid-sparing potential (reducing need for corticosteroids)
• Safety profile consistent with other trials

Current Development:

• Phase 3 GARDENIA study: Currently enrolling
• Timeline: Potential approval 2027-2028 if successful

SLE Background:

Systemic lupus erythematosus affects:

• ~300,000 U.S. patients
• Predominantly women (9:1 female:male ratio)
• Multiple organ systems (skin, joints, kidneys, blood, brain)
• Driven by autoantibodies attacking self-tissues

Current SLE Therapies:

• Corticosteroids: First-line but significant side effects
• Hydroxychloroquine: Maintenance therapy
• Immunosuppressants: Azathioprine, mycophenolate
• Biologics: Benlysta (belimumab, anti-BAFF)

Nipocalimab’s Differentiation:

As FcRn blocker:

• Reduces all IgG autoantibodies (vs. targeting specific pathways)
• Broad mechanism applicable across autoimmune diseases
• Potential for use alone or with existing therapies
• Addresses multiple autoantibody-mediated pathologies simultaneously

Market Opportunity:

SLE alone: $2-3 billion annual market potential

Across all indications with Fast Track:

• HDFN: Niche but high unmet need
• wAIHA: First potential approved therapy
• Myasthenia gravis: Competition with existing therapies
• Sjögren’s: Large unmet need, no approved therapies
• SLE: Major market opportunity

Combined franchise potential: $5-10 billion at peak

Competitive Context:

vs. Argenx’s Vyvgart (efgartigimod):

Both are FcRn blockers but:

• Vyvgart: Approved for myasthenia gravis, expanding to other indications
• Nipocalimab: Multiple concurrent development programs, potentially reaching market in several indications near-simultaneously

The “race against Argenx for second-wave markets is intensifying” as both companies pursue overlapping indications.

J&J’s Competitive Advantages:

• Global commercial infrastructure
• Multiple simultaneous development programs
• Financial resources for large trials
• Manufacturing scale-up capability

What to Watch: GARDENIA Phase 3 results, additional indication trial readouts, regulatory filing timelines, and head-to-head data vs. Vyvgart if available.

Regulatory Developments

Regenxbio RGX-121 Complete Response Letter

What Happened: The FDA issued a Complete Response Letter for RGX-121, Regenxbio’s Hunter syndrome gene therapy, citing concerns about:

• Phenotype classification
• External control comparability
• Whether CSF heparan sulfate levels adequately predict clinical benefit

FDA Recommendation:

The agency recommended a prospective, randomized, sham surgery-controlled study.

Hunter Syndrome Background:

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked lysosomal storage disease causing:

• Accumulation of glycosaminoglycans (GAGs)
• Progressive organ damage
• Developmental delays
• Early mortality

RGX-121 Approach:

Gene therapy delivered:

• Directly to CNS via intrathecal injection
• Providing functional enzyme (iduronate-2-sulfatase)
• Reducing GAG accumulation in brain

The External Control Problem:

Regenxbio compared treated patients to:

• Natural history data from untreated patients
• Historical controls from databases

FDA concerns:

• Patient phenotypes may not be truly comparable
• Natural history data quality/consistency
• Whether biomarker (CSF heparan sulfate) reliably predicts clinical benefit

Sham Surgery Control Requirement:

Similar to uniQure’s AMT-130, FDA is demanding:

• Prospective randomized trial
• Sham surgery control (placebo patients undergo procedure without therapy)
• Direct controlled comparison rather than historical data

The Regulatory Pattern:

This CRL, combined with Monday’s uniQure rejection, establishes clear FDA position:

For invasive gene therapies (CNS delivery requiring procedures), the agency will not accept:

• External natural history controls
• Surrogate biomarker endpoints alone
• Uncontrolled single-arm studies

The agency requires:

• Prospective randomized trials
• Sham-controlled designs for surgical interventions
• Clinical outcome measures, not just biomarkers

Regenxbio’s Response:

Plans to:

• Request Type A meeting with FDA
• Discuss prospective trial design
• Consider resubmission with longer-term data from current patients
• Evaluate feasibility of sham-controlled trial

Operational Challenges:

Similar to uniQure:

• Sham surgery ethics and enrollment
• Extended timeline (years for new trial)
• Substantial additional costs
• Patient population size limitations

What to Watch: Type A meeting outcomes, trial design discussions, and whether company can identify path forward without full sham-controlled trial.

uniQure AMT-130 Confirmation

What Happened: The FDA confirmed it “strongly recommends” a prospective, randomized, double-blind, sham surgery-controlled Phase 3 study before uniQure can submit a BLA for AMT-130 in Huntington’s disease.

Significance:

This represents “significant reversal from prior FDA communications that had endorsed the Phase 1/2 program for accelerated approval.”

Impact:

uniQure shares fell more than 35%, reflecting:

• Multi-year delay to potential approval (2029+ vs. 2026-2027 hope)
• Hundreds of millions in additional development costs
• Operational feasibility questions about sham-controlled Huntington’s trial
• Financing needs to fund extended development

The Broader CNS Gene Therapy Re-Rating:

Two CRLs/rejections in 48 hours (uniQure, Regenxbio) force massive risk recalibration for:

• Huntington’s disease programs
• Other neurodegenerative gene therapies
• Duchenne muscular dystrophy CNS-delivery approaches
• Any invasive gene therapy relying on external controls

Under CBER Director Prasad, natural history and external controls are no longer sufficient for gene therapy approvals—even when previously endorsed by the agency in prior meetings.

Clinical & Research Updates

COUR Pharma: CNP-104 Primary Biliary Cholangitis Data

What Happened: COUR Pharma announced positive one-year results from Phase 2a study of CNP-104 in primary biliary cholangitis (PBC).

Results:

• Restoration of immune tolerance
• Sustained, statistically significant separation of liver stiffness vs. placebo
• Effect observed twelve months after only two doses

CNP-104 Mechanism:

The therapy uses nanoparticle technology to:

• Deliver disease-relevant antigens to immune system
• Induce antigen-specific immune tolerance
• Reduce autoimmune attack on bile ducts

PBC Background:

Autoimmune disease causing:

• Progressive destruction of bile ducts
• Cholestasis (bile accumulation)
• Liver fibrosis and cirrhosis
• Eventually requiring transplant

Current Treatment:

• Ursodeoxycholic acid (UDCA): First-line, slows progression
• Obeticholic acid: Second-line for inadequate UDCA response
• Limited options beyond these

Why Two-Dose, One-Year Effect Matters:

If confirmed:

• Infrequent dosing improves compliance and convenience
• Durable effect suggests true immune tolerance vs. symptomatic treatment
• Differentiation from chronic daily medications

What to Watch: Additional safety and efficacy data, dose selection for Phase 3, regulatory discussions.

LongBio Pharma: LP-003 Superiority vs. Xolair

What Happened: LongBio Pharma reported positive Phase 2 results in chronic spontaneous urticaria at AAAAI Annual Meeting, demonstrating statistically superior efficacy versus Novartis’s Xolair (omalizumab) in head-to-head comparison.

LP-003 Profile:

• Anti-IgE antibody with 860-fold greater IgE binding affinity than Xolair
• Designed for enhanced potency through improved binding

Market Context:

Xolair generates billions annually across multiple allergic indications:

• Chronic spontaneous urticaria
• Moderate-to-severe asthma
• Chronic rhinosinusitis with nasal polyps
• Food allergy

Significance:

If Phase 3 confirms superiority, LP-003 would become:

• First new anti-IgE drug launched globally in over 20 years
• Potentially best-in-class alternative to Xolair

Development Timeline:

• Phase 3 CSU: Expected to start H1 2026
• BLA submission (seasonal allergic rhinitis): Q3 2026 to China’s NMPA
• Global development: Dependent on additional partnerships/funding

Corporate Developments

Esperion: $75M+ Corstasis Acquisition

What Happened: Esperion Therapeutics entered definitive agreement to acquire Corstasis Therapeutics, gaining Enbumyst (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure.

Deal Terms:

• Upfront: $75 million
• Milestones: Up to $180 million
• Royalties: Worldwide royalties on sales
• Close: Expected Q2 2026

Enbumyst Profile:

• Active ingredient: Bumetanide (loop diuretic)
• Formulation: Nasal spray
• Indication: Edema from congestive heart failure
• FDA approval: Already approved

Rationale:

For Esperion:

• Adds commercial-stage cardiovascular asset
• Synergies with existing CV sales force
• Diversifies beyond cholesterol-lowering franchise
• Immediate revenue contribution

Market Opportunity:

Acute edema management in CHF represents $4+ billion market. Nasal spray offers:

• Rapid onset (nasal absorption faster than oral)
• Convenient alternative to IV diuretics
• Home or outpatient use vs. hospitalization

Commercial Challenges:

• Bumetanide is off-patent, generic molecule
• Payer resistance to “nasal premium” over generic oral bumetanide
• Competition from IV diuretics in hospital, oral generics outpatient
• MannKind’s Furoscix (furosemide subcutaneous) competes in acute setting

Success Depends On:

• Securing favorable formulary coverage
• Demonstrating value justifying premium vs. generics
• Physician adoption for appropriate use cases
• Sales force execution

BioMarin/Amicus: Merger Approval

What Happened: Amicus Therapeutics stockholders formally approved the $4.8 billion BioMarin acquisition at special meeting.

Vote Results:

• Shares represented: 74.79%
• Approval: Overwhelming majority in favor

Transaction Details:

BioMarin acquires:

• Galafold (migalastat): Oral therapy for Fabry disease
• Pombiliti + Opfolda: Enzyme replacement therapy for Pompe disease
• Additional pipeline assets

Expected Close: Q2 2026

Strategic Rationale:

• Expands BioMarin’s rare disease portfolio
• Adds commercial-stage revenue-generating assets
• Particularly important following Roctavian withdrawal
• Diversifies beyond achondroplasia (facing YUVIWEL competition)

Royalty Pharma: Kenneth Sun Asia Appointment

What Happened: Royalty Pharma appointed Kenneth Sun (ex-Morgan Stanley) as SVP and Head of Asia, based in Hong Kong, effective May 2026.

Strategic Context:

Asian out-licensing transaction value:

• 2025: Exceeded $130 billion in announced deals
• 2021: Approximately $14 billion
• Growth: ~9x increase in four years

Why This Matters:

Asian biotechs transitioning from:

• Me-too generics and biosimilars
• To first-in-class innovative assets
• Increasingly out-licensing to Western pharmaceutical companies

Royalty Model Fit:

Asian biotechs seeking:

• Non-dilutive capital for development
• Validation from experienced investors
• Maintained equity upside
• Access to Western markets through partners

Royalty Pharma provides capital in exchange for future royalties, perfectly suited to this market.

The APAC Pivot:

Kenneth Sun’s appointment signals:

• Next decade of cash-flow biopharma driven by Chinese innovators
• Royalty opportunity shifted decisively eastward
• Institutional capital following deal flow to Asia

Policy & Public Health

CMS CRUSH Initiative

What Happened: CMS is accepting comments on its Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) request for information, seeking input on strengthening fraud prevention across Medicare and Medicaid.

Focus Areas:

• Identifying suspicious billing patterns
• Improving fraud detection systems
• Strengthening enforcement mechanisms
• Protecting program integrity

Strategic Themes

The Non-Dilutive Capital Wave

Two massive deals in 48 hours signal definitive shift:

• Teva/Blackstone: $400M for duvakitug
• Zymeworks/Royalty Pharma: $250M (referenced in Pro section)

The 2026 Playbook:

For Phase 3-ready biotechs with de-risked assets:

• Royalty monetization over equity dilution
• Milestone-linked financing from private equity
• Preserves shareholder upside in tight capital markets
• Asset-specific risk vs. company-wide debt

Who Benefits:

Companies with:

• Positive Phase 2 data
• Large market opportunities
• Clear regulatory paths
• Institutional validation (partnerships, Fast Tracks)

The Sham Control Re-Rating

FDA’s position now crystal clear through three data points in one week:

• uniQure AMT-130: Rejection, sham-controlled Phase 3 required
• Regenxbio RGX-121: CRL, sham-controlled Phase 3 recommended
• Both: External controls insufficient despite prior endorsement

Implications:

All CNS gene therapies requiring invasive delivery must anticipate:

• Prospective randomized trials
• Sham surgery controls
• Multi-year timelines
• Substantially higher costs

Programs must structurally re-price regulatory risk.

TL1A Validation

The $400M Blackstone financing cements TL1A as “the next TNF” in IBD. Multiple competitors developing inhibitors creates race for first approval and market share in large IBD population.

Frequently Asked Questions

Q: What is TL1A and why is it called “the next TNF”?

TL1A is a TNF superfamily member highly expressed in inflamed gut tissue. Called “the next TNF” because genetic studies link it to IBD, blocking it reduces inflammation, and it offers alternative mechanism for anti-TNF non-responders—similar role TNF-alpha played 20+ years ago before Remicade and Humira dominated the market.

Q: How does non-dilutive financing benefit shareholders vs. traditional equity raises?

Traditional equity raises dilute existing shareholders, giving new investors ownership at potentially depressed valuations. Non-dilutive financing (royalties, milestones) provides capital without issuing new shares, preserving upside for current shareholders. Blackstone gets compensated through low single-digit royalties on future sales rather than equity ownership.

Q: Why does cytokine release syndrome matter for autoimmune T-cell engagers?

In oncology, CRS risk is acceptable given disease severity. Autoimmune patients are typically younger, otherwise healthy, and may need chronic treatment. Severe CRS would require intensive monitoring, limit adoption, and could be life-threatening in outpatient settings. Antengene’s masking technology reducing CRS is critical for commercial viability.

Q: What is FcRn and how does blocking it treat autoimmune disease?

FcRn (neonatal Fc receptor) recycles IgG antibodies, extending their half-life. Blocking FcRn prevents recycling, accelerating clearance of pathogenic autoantibodies driving autoimmune diseases. Nipocalimab reduces autoantibody levels across multiple diseases by this mechanism.

Q: Can Regenxbio avoid sham-controlled trial like FDA demanded?

Unlikely based on precedent. FDA has now required sham controls for uniQure and recommended them for Regenxbio. Type A meeting may clarify whether additional long-term data from current patients could suffice, but agency appears committed to prospective controlled trials for invasive CNS gene therapies.

Q: Why would payers resist Enbumyst if it’s FDA-approved?

Bumetanide is off-patent generic available as cheap oral pills or IV formulation. Payers may view nasal spray as unnecessary premium over existing options. Esperion must demonstrate value—faster onset, better outcomes, reduced hospitalizations—justifying higher cost vs. generics to secure favorable coverage.

Q: How can nipocalimab compete in so many indications simultaneously?

FcRn blockade is pan-IgG mechanism applicable across all autoantibody-driven diseases. J&J can run trials in multiple indications simultaneously, building comprehensive safety database while pursuing sequential approvals. This “rolling review” strategy aims to capture multiple markets before competitors.

Q: What does “significant reversal from prior FDA communications” mean for uniQure?

FDA apparently gave uniQure positive feedback in earlier meetings about pursuing accelerated approval based on Phase 1/2 data. The demand for sham-controlled Phase 3 reverses that guidance, suggesting shifting regulatory standards under CBER Director Prasad. Companies can no longer rely on prior feedback remaining consistent.

About BioMed Nexus

BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma.

Get the daily brief delivered before market open — Subscribe at biomednexus.com

Pro members access institutional analysis including scenario modeling, competitive positioning frameworks, and probability-weighted outcomes.

Explore Pro Membership →

This analysis is for informational purposes and does not constitute investment advice. All information verified as of March 4, 2026.